tirzepatide antibodies (Mounjaro) Pharmacogenomics of Tirzepatide: Genomic Insights

Safety and Monitoring: Our medical team monitors your progress closely, managing any potential side effects

Helps the body convert fat cells into energy.

Bliddal, H., Bays, H., Czernichow, S., Uddn Hemmingsson, J., Hjelmesth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vlez Snchez, P., Wharton, S., Wizert, A., & Kristensen, L

Most patients experience tirzepatide-related dizziness for 1014 days after each dose increase, with peak symptoms occurring 37 days post-injection

Some anticoagulant medications, including unfractionated heparin, increase APTT, reflecting prolongation of the time needed for clot formation